Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 22, 2025
Principal Event: Entry into a Material Definitive Agreement regarding the repurchase of warrants held by the Company in Scilex Holding Company.
Key Financial Metrics and Transaction Details
This filing details a specific transaction rather than periodic financial results. Key monetary values include:
- Warrant Repurchase Amount: $27,000,000 total aggregate purchase price for the repurchase of 6,500,000 Scilex warrants.
- Option Payment Amount: $1,500,000 paid by Scilex to Oramed in two installments (due August 8, 2025, and December 16, 2025).
- Tranche A Note: Existing Senior Secured Promissory Note principal of $101,875,000.
- Warrant Exercise Price: $0.01 per share (clarified as not adjusted by Scilex's reverse stock split).
Note: The filing does not provide current revenue, profit, cash flow, or liquidity metrics for Oramed Pharmaceuticals Inc.
Material Changes and Clarifications
- Warrant Repurchase Agreement: Oramed granted Scilex an option to repurchase 6,500,000 warrants in two tranches:
- Tranche 1: 3,130,000 warrants for $13,000,000 (deadline: September 30, 2025).
- Tranche 2: 3,370,000 warrants for $14,000,000 (deadline: December 31, 2025).
- Note Extension: If Scilex completes the repurchase and pays all amounts, the maturity of the $101,875,000 Tranche A Note is extended to March 31, 2026, and any make-whole payment upon prepayment is waived.
- Correction of Prior Disclosure: The Company clarified a statement in its March 31, 2025 Form 10-Q. The 10-Q incorrectly stated the exercise price of the warrants was $0.35 per share following Scilex's reverse stock split. The filing confirms the price remains $0.01 per share. The Company states this clarification has no impact on its financial position or results of operations.
Outlook, Risks, and Contingencies
- Exercise Restriction: Oramed agreed not to exercise the subject warrants until the Option Agreement is terminated or Scilex forfeits its rights.
- Termination Rights: Oramed may terminate the agreement if Scilex fails to make required payments or does not exercise the option by the applicable dates.
- Stockholder Approval Cap: If the agreement is terminated, Scilex must use commercially reasonable efforts to obtain stockholder approval to allow Oramed to exercise warrants beyond the 19.9% ownership cap.
- Management Commentary: The filing focuses on contractual terms and clarifications; no forward-looking guidance on Oramed's core pharmaceutical operations is provided.
Investor Verification Checklist
- Verify the receipt of the $1,500,000 Option Payment in the two scheduled installments (August and December 2025).
- Monitor whether Scilex exercises the option to repurchase the warrants by the September 30 and December 31, 2025 deadlines.
- Confirm the extension of the Tranche A Note maturity date to March 31, 2026, contingent on full payment of the repurchase amounts.
- Review the full text of the Option Agreement (Exhibit 10.1) for redacted confidential terms.